Potential use of miR-21-5p as a marker for cardiovascular disease progression after COVID-19

Abstract

This study evaluates the significance of blood microRNA (miR-21-5p) levels as a biomarker for the development or progression of cardiovascular diseases after COVID-19. The levels of circulating miR-21-5p in the blood were analyzed in 120 patients with cardiovascular diseases recovering from COVID-19. Based on inclusion and exclusion criteria, six groups of patients were formed with 20 patients in each of them. All patients had previously suffered from COVID-19 required hospital care. The groups were divided by the presence of previously verified coronary heart disease, hypertension, and atherosclerosis, as well as the absence of diagnosed cardiovascular diseases. The patients were also divided into those with worsening of preexisting circulatory system diseases or their onset and those without such diseases. All patients underwent circulatory system examination before and after COVID-19. Statistically significant differences in miR-21-5p levels were revealed when comparing groups with previously verified coronary heart disease with and without worsening, as well as groups without preexisting cardiovascular diseases. No statistically significant differences in cardiovascular diseases progression were identified when comparing patients with previously verified hypertension or atherosclerosis. Therefore, blood miR-21-5p appears to be a promising biomarker for assessing the progression of coronary heart disease, including in patients recovering from COVID-19. This method correlates with clinical observations in patients with coronary heart disease, as well as diagnostic investigation data. Further studies on larger cohorts of patients with cardiovascular diseases and follow-up monitoring of miR-21-5p expression levels may increase the informative value of this biomarker. It could aid in clinical decision-making process and follow-up monitoring of patients with such diseases in order to reduce adverse complications.

Keywords

COVID-19 / atherosclerosis / hypertension / coronary heart disease / laboratory diagnostics / microribonucleic acid (miR-21-5p) / molecular genetic testing / circulatory system

References

[1] Bichurin DR, Atmaikina OV, Cherepanova OA. Cardiovascular diseases. Regional aspect. International Research Journal. 2023;8(134). doi: 10.23670/IRJ.2023.134.103

[2] Бичурин Д.Р., Атмайкина О.В., Черепанова О.А. Сердечно-сосудистые заболевания. Региональный аспект // Международный научно-исследовательский журнал. 2023. № 8 (134). doi: 10.23670/IRJ.2023.134.103

[3] Bichurin DR, Atmaikina OV, Cherepanova OA. Cardiovascular diseases. Regional aspect. International Research Journal. 2023;8(134). doi: 10.23670/IRJ.2023.134.103

[4] Andreenko AA, Andreichuk YuV, Arsent’ev VG, et al. Infection caused by SARS-COV-2. Kryukov EV, ed. Saint Petersburg; 2023. 260 p. (In Russ.) EDN: QFKFPFCOVID-19

[5] Андреенко А.А., Андрейчук Ю.В., Арсентьев В.Г., и др. Инфекция, вызванная SARS-COV-2 / под ред. Е.В. Крюкова. Санкт-Петербург, 2023. 260 с. EDN: QFKFPFCOVID-19

[6] Andreenko AA, Andreichuk YuV, Arsent’ev VG, et al. Infection caused by SARS-COV-2. Kryukov EV, ed. Saint Petersburg; 2023. 260 p. (In Russ.) EDN: QFKFPFCOVID-19

[7] Berezovskaya GA, Petrishchev NN, Volkova EV, et al. Defeat of the cardiovascular system in the new coronavirus infection COVID-19. Cardiology: news, opinion, training. 2022;10(4):37–47. doi: 10.33029/2309-1908-2022-10-4-37-47

[8] Березовская Г.А., Петрищев Н.Н., Волкова Е.В., и др. Поражение сердечно-сосудистой системы при новой коронавирусной инфекции COVID-19 // Кардиология: Новости. Мнения. Обучение. 2022. Т. 10, № 4. С. 37–46. doi: 10.33029/2309-1908-2022-10-4-37-47

[9] Berezovskaya GA, Petrishchev NN, Volkova EV, et al. Defeat of the cardiovascular system in the new coronavirus infection COVID-19. Cardiology: news, opinion, training. 2022;10(4):37–47. doi: 10.33029/2309-1908-2022-10-4-37-47

[10] Melnikova LV, Lokhina TV, Berenstein NV, and others. Cardiovascular consequences of COVID-19: pathogenesis, diagnosis and treatment. Lechaschi Vrach. 2021;(7):8–13. (In Russ.) doi: 10.51793/OS.2021.24.7.002

[11] Мельникова Л.В., Лохина Т.В., Беренштейн Н.В., и др. Сердечно-сосудистые последствия перенесенного COVID-19: патогенез, диагностика и лечение // Лечащий врач. 2021. № 7. С. 8–13. doi: 10.51793/OS.2021.24.7.002

[12] Melnikova LV, Lokhina TV, Berenstein NV, and others. Cardiovascular consequences of COVID-19: pathogenesis, diagnosis and treatment. Lechaschi Vrach. 2021;(7):8–13. (In Russ.) doi: 10.51793/OS.2021.24.7.002

[13] Kryukov EV, Trishkin DV, Salukhov VV, et al. Experience of military medicine in the fight against the new coronavirus infection. Vestnik Rossijskoj Akademii Nauk. 2022;92(7):699–706. (In Russ.) EDN: HIPURN doi: 10.1134/S1019331622040050

[14] Крюков Е.В., Тришкин Д.В., Салухов В.В., и др. Опыт военной медицины в борьбе с новой коронавирусной инфекцией // Вестник Российской академии наук. 2022. Т. 92, № 7. С. 699–706. EDN: HIPURN doi: 10.1134/S1019331622040050

[15] Kryukov EV, Trishkin DV, Salukhov VV, et al. Experience of military medicine in the fight against the new coronavirus infection. Vestnik Rossijskoj Akademii Nauk. 2022;92(7):699–706. (In Russ.) EDN: HIPURN doi: 10.1134/S1019331622040050

[16] Felekkis K, Touvana E, Stefanou C, et al. MicroRNAs: A newly described class of encoded molecules that play a role in health and disease. Hippokratia. 2010;14(4):236–240.

[17] Felekkis K., Touvana E., Stefanou C., et al. MicroRNAs: A newly described class of encoded molecules that play a role in health and disease // Hippokratia. 2010. Vol. 14, N 4. P. 236–240.

[18] Felekkis K, Touvana E, Stefanou C, et al. MicroRNAs: A newly described class of encoded molecules that play a role in health and disease. Hippokratia. 2010;14(4):236–240.

[19] Gumilevskiy BYu, Moskalev AV, Gumilevskay OP, et al. Features of immunopathogenesis of a new coronavirus infection. Bulletin of the Russian Military Medical Academy. 2021;23(1):187–198. doi: 10.17816/brmma.63654

[20] Гумилевский Б.Ю., Москалев А.В., Гумилевская О.П., и др. Особенности иммунопатогенеза новой коронавирусной инфекции // Вестник Российской военно-медицинской академии. 2021. Т. 23, № 1. С. 187–198. doi: 10.17816/brmma.63654

[21] Gumilevskiy BYu, Moskalev AV, Gumilevskay OP, et al. Features of immunopathogenesis of a new coronavirus infection. Bulletin of the Russian Military Medical Academy. 2021;23(1):187–198. doi: 10.17816/brmma.63654

[22] Romaine SPR, Tomaszewski M, Condorelli G, et al. MicroRNAs in cardiovascular disease: An introduction for clinicians. Heart. 2015;101(12):921–928. doi: 10.1136/heartjnl–2013–305402

[23] Romaine S.P.R., Tomaszewski M., Condorelli G., et al. MicroRNAs in cardiovascular disease: An introduction for clinicians // Heart. 2015. Vol. 101, N 12. P. 921–928. doi: 10.1136/heartjnl-2013-305402

[24] Romaine SPR, Tomaszewski M, Condorelli G, et al. MicroRNAs in cardiovascular disease: An introduction for clinicians. Heart. 2015;101(12):921–928. doi: 10.1136/heartjnl–2013–305402

[25] Peters LJF, Biessen EAL, Hohl M, et al. Small things matter: Relevance of microRNAs in cardiovascular disease. Front Physiol. 2020;11:1–14. doi: 10.3389/fphys.2020.00793

[26] Peters L.J.F., Biessen E.A.L., Hohl M., et al. Small things matter: Relevance of microRNAs in cardiovascular disease // Front Physiol. 2020. Vol. 11. P. 1–14. doi: 10.3389/fphys.2020.00793

[27] Peters LJF, Biessen EAL, Hohl M, et al. Small things matter: Relevance of microRNAs in cardiovascular disease. Front Physiol. 2020;11:1–14. doi: 10.3389/fphys.2020.00793

[28] Marchi R, Sugita B, Centa A, et al. The role of microRNAs in modulating SARS-CoV-2 infection in human cells: A systematic review. Infect Genet Evol. 2021;91:104832. doi: 10.1016/j.meegid.2021.104832

[29] Marchi R., Sugita B., Centa A., et al. The role of microRNAs in modulating SARS-CoV-2 infection in human cells: A systematic review // Infect Genet Evol. 2021. Vol. 91. P. 104832. doi: 10.1016/j.meegid.2021.104832

[30] Marchi R, Sugita B, Centa A, et al. The role of microRNAs in modulating SARS-CoV-2 infection in human cells: A systematic review. Infect Genet Evol. 2021;91:104832. doi: 10.1016/j.meegid.2021.104832

[31] Garg A, Seeliger B, Derda AA, et al. Circulating cardiovascular microRNAs in critically ill COVID-19 patients. Eur J Heart Fail. 2021;23(3):468–475. doi: 10.1002/ejhf.2096

[32] Garg A., Seeliger, B., Derda A.A., et al. Circulating cardiovascular microRNAs in critically ill COVID-19 patients // Eur J Heart Fail. 2021. Vol. 23, N 3. P. 468–475. doi: 10.1002/ejhf.2096

[33] Garg A, Seeliger B, Derda AA, et al. Circulating cardiovascular microRNAs in critically ill COVID-19 patients. Eur J Heart Fail. 2021;23(3):468–475. doi: 10.1002/ejhf.2096

[34] Pieri M, Vayianos P, Nicolaidou V, et al. Alterations in circulating miRNA levels after infection with SARS-CoV-2 could contribute to the development of cardiovascular diseases: What We Know So Far. Int J Mol Sci. 2023;24(3):1–14. doi: 10.3390/ijms24032380

[35] Pieri M., Vayianos P., Nicolaidou V., et al. Alterations in Circulating miRNA Levels after Infection with SARS-CoV-2 Could contribute to the development of cardiovascular diseases: what we know so far // Int J Mol Sci. 2023. Vol. 24, N 3. P. 1–14. doi: 10.3390/ijms24032380

[36] Pieri M, Vayianos P, Nicolaidou V, et al. Alterations in circulating miRNA levels after infection with SARS-CoV-2 could contribute to the development of cardiovascular diseases: What We Know So Far. Int J Mol Sci. 2023;24(3):1–14. doi: 10.3390/ijms24032380

[37] Chistiakov DA, Sobenin IA, Orekhov AN, et al. Human miR-221/222 in physiological and atherosclerotic vascular remodeling. BioMed. Res. Int. 2015;2015:354517. doi: 10.1155/2015/354517

[38] Chistiakov D.A., Sobenin I.A., Orekhov A.N., et al. Human miR-221/222 in physiological and atherosclerotic vascular remodeling // BioMed Res. Int. 2015. Vol. 2015. P. 354517. doi: 10.1155/2015/354517

[39] Chistiakov DA, Sobenin IA, Orekhov AN, et al. Human miR-221/222 in physiological and atherosclerotic vascular remodeling. BioMed. Res. Int. 2015;2015:354517. doi: 10.1155/2015/354517

[40] Cengiz M, Yavuzer S, Avci BK, et al. Circulating miR-21 and eNOS in subclinical atherosclerosis in patients with hypertension. Clin Exp Hypertens. 2015;37(8):643–649. doi: 10.3109/10641963.2015.1036064

[41] Cengiz M., Yavuzer S., Avci, B.K., et al. Circulating miR-21 and eNOS in subclinical atherosclerosis in patients with hypertension // Clin Exp Hypertens. 2015. Vol. 37, N 8. P. 643–649. doi: 10.3109/10641963.2015.1036064

[42] Cengiz M, Yavuzer S, Avci BK, et al. Circulating miR-21 and eNOS in subclinical atherosclerosis in patients with hypertension. Clin Exp Hypertens. 2015;37(8):643–649. doi: 10.3109/10641963.2015.1036064

[43] Zhu N, Zhang D, Chen S, et al. Endothelial enriched microRNAs regulate angiotensin II-induced endothelial inflammation and migration. Atherosclerosis. 2011;215(2):286–293. doi: 10.1016/j.atherosclerosis.2010.12.024

[44] Zhu N., Zhang D., Chen S, et al. Endothelial enriched microRNAs regulate angiotensin II-induced endothelial inflammation and migration // Atherosclerosis. 2011. Vol. 215, N 2. P. 286–293. doi: 10.1016/j.atherosclerosis.2010.12.024

[45] Zhu N, Zhang D, Chen S, et al. Endothelial enriched microRNAs regulate angiotensin II-induced endothelial inflammation and migration. Atherosclerosis. 2011;215(2):286–293. doi: 10.1016/j.atherosclerosis.2010.12.024

[46] Kumar A, Fausto A. Robbins and Cotran in pathologic basis of disease. 10th ed. Spain: Elsevier España, S.L.U.; 2020. Р. 1392.

[47] Kumar A., Fausto A. Robbins and Cotran in pathologic basis of disease. 10th ed. Spain: Elsevier España, S.L.U., 2020. Р. 1392.

[48] Kumar A, Fausto A. Robbins and Cotran in pathologic basis of disease. 10th ed. Spain: Elsevier España, S.L.U.; 2020. Р. 1392.

[49] Sanlialp M, Dodurga Y, Uludag B, et al. Peripheral blood mononuclear cell microRNAs in coronary artery disease. J Cell Biochem. 2020;121(4):3005–3009. doi: 10.1002/jcb.29557

[50] Sanlialp M., Dodurga Y., Uludag B., et al. Peripheral blood mononuclear cell microRNAs in coronary artery disease // J Cell Biochem. 2020. Vol. 121, N 4. P. 3005–3009. doi: 10.1002/jcb.29557

[51] Sanlialp M, Dodurga Y, Uludag B, et al. Peripheral blood mononuclear cell microRNAs in coronary artery disease. J Cell Biochem. 2020;121(4):3005–3009. doi: 10.1002/jcb.29557

[52] Chen Z, Song S, Zhu J, et al. Regulatory mechanism of MiR-21 in formation and rupture of intracranial aneurysm through JNK signaling pathway-mediated inflammatory response. Int J Clin Exp Pathol. 2020;13(7):1834–1841. doi: 10.3389/fgene.2022.875007

[53] Chen Z., Song S., Zhu J., et al. Regulatory mechanism of MiR-21 in formation and rupture of intracranial aneurysm through JNK signaling pathway-mediated inflammatory response // Int J Clin Exp Pathol. 2020. Vol. 13, N 7. P. 1834–1841. doi: 10.3389/fgene.2022.875007

[54] Chen Z, Song S, Zhu J, et al. Regulatory mechanism of MiR-21 in formation and rupture of intracranial aneurysm through JNK signaling pathway-mediated inflammatory response. Int J Clin Exp Pathol. 2020;13(7):1834–1841. doi: 10.3389/fgene.2022.875007

[55] Ren W, Hou J, Yang C, et al. Extracellular vesicles secreted by hypoxia pre-challenged mesenchymal stem cells promote non-small cell lung cancer cell growth and mobility as well as macrophage M2 polarization via miR-21-5p delivery. J Exp Clin Cancer Res. 2019;38(1):62. doi: 10.1186/s13046-019-1027-0

[56] Ren W., Hou J., Yang C., et al. Extracellular vesicles secreted by hypoxia pre-challenged mesenchymal stem cells promote non-small cell lung cancer cell growth and mobility as well as macrophage M2 polarization via miR-21-5p delivery // J Exp Clin Cancer Res. 2019. Vol. 38, N 1. Р. 62. doi: 10.1186/s13046-019-1027-0

[57] Ren W, Hou J, Yang C, et al. Extracellular vesicles secreted by hypoxia pre-challenged mesenchymal stem cells promote non-small cell lung cancer cell growth and mobility as well as macrophage M2 polarization via miR-21-5p delivery. J Exp Clin Cancer Res. 2019;38(1):62. doi: 10.1186/s13046-019-1027-0

Funding

Правительство Российской ФедерацииThe Russian Government

RIGHTS & PERMISSIONS

Eco-Vector